Preclinical Drug Development Planning

Preclinical Development Handbook: Toxicology

Volumn , Issue , 2007, Pages 1-63

  Bhogal, Nirmala ^a   Combes, Robert ^a   Balls, Michael ^a  

^a RUSSELL AND BURCH HOUSE   (United Kingdom)

Author keywords

Analogue based minimization; Antisense bioaccumulation; Druggable genome

Indexed keywords

EID: 84889354063     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249055.ch1     Document Type: Chapter

References (141)

1. Challenge and Opportunity on the Critical Path to New Medical Products. US FDA March 2004. Available from http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html(accessed 29 January 2007).
2. Guidance for Industry:Fast Track Drug Development Programs-Designation, Development, and Application Review. Rockvill, MD:US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research(CDER), Center for Biologics Evaluation and Research(CBER); January 2006. Procedural Revision 2. Available from http://www.fda.gov/cber/gdlns/fsttrk.pdf(accessed 29 January 2007).
3. Schwieterman WD. Regulating biopharmaceuticals under CDE versus CBER:an insider's perspective. Drug Discov Today 2006;11(19-20):945-951.
4. Organisation for Economic Co-operation and Development. Chemcials Testing Guidelines. Section 4:Health Effects. Available from http://www.oecd.org/document/55/0,2340,en_2649_34377_2349687_1_1_1_1,00.html(accessed 29 January 2007).
5. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5(12): 993-996.
6. Wilson S, Bergsma D. Orphan G-protein coupled receptors:novel drug targets for the pharmaceutical industry. Drug Des Discov 2000; 17(2): 105-114.
7. Cancer Genome Anatomy Project:National Cancer Institute. Available from www.ncbi.nlm.nih.gov/CGAP(accessed 29 January 2007).
8. Genomes on-line database version 2. Available from http://www.genomesonline.org/(accessed 29 January 2007).
9. Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD. Computational prediction of human metabolic pathways from the complete human genome. Genome(Biol) 2004 ;6(1):http://genomebiology.com/2004/6/1/R2 (accessed 29 January 2007).
10. Salzberg SL, White O, Peterson J, Eisen JA. Microbial genes in the human genome:lateral transfer or gene loss? Science 2001; 292(5523): 1903-1906.
11. Steinmetz LM, Scharfe C, Deutschbauer AM, Mokranjac D, Herman ZS, Jones T, Chu AM, Giaever G, Prokisch H, Oefner PJ, Davis RW. Systematic screen for human disease genes in yeast. Nat Genet 2002;31:400-404.
12. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburtty K, Simon J, Bard M, Friend SH. Functional discovery via a compendium of expression profiles. Cell 2000;102:109-126.
13. Kumar A, Agarwal S, Heyman JA, Matson S, Heidtman M, Piccirillo S, Umansky L, Drawid A, Jansen R, Liu Y, Cheung K-H, Miller P, Gerstein M, Roeder GS, Snyder M. Subcellular localization of the yeast proteome. Genes Dev 2002; 16(6): 707-719.
14. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003;302:1772-1775.
15. Griffioen G, Duhamel H, Van Damme N, Pellens K, Zabrocki P, Pannecouque C, van Leuven F, Winderickx J, Wera S. A yeast-based model of α-synucleinopathy identifies compounds with therapeutic potential. Biochem Biophys Acta 2006;1762:312-318.
16. Versele M, Lemaire K, Thevelein JM. Sex and sugar in yeast:two distinct GPCR systems. EMBO Rep 2001;2:574-579.
17. Pausch MH, Lai M, Tseng E, Paulsen J, Bates B, Kwak S. Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae. Biochem Biophys Res Commun 2004;324:171-177.
18. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811.
19. Metzstein MM, Stanfield GM, Horvitz HR. Genetics of programmed cell death in C. elegans:past, present and future. Trends Genet 1998; 14(10): 410-416.
20. Nichols CD. Drosophila melanogaster neurobiology, neuropharmacology, and how the fly can inform central nervous system drug discovery. Pharmacol Ther 2006; 112(3): 677-700.
21. Kellenberger E, Muller P, Schalon C, Bret G, Foata N, Rognan D. Sc- PDB:an annotated database of druggable binding sites from the protein data bank. J Chem Inf Model 2006;46:717-727.
22. Tapolczay D, Chorlton A, McCubbin Q. Probing drug structure improves the odds. Curr Opin Drug Discov Dev 2000;April:30-33.
23. Schreiber SL. Target-oriented and diversity-oriented organis synthesis in drug discovery. Science 2000; 287(5460): 1964-1969.
24. Villar HO, Yan J, Hansen MR. Using NMR for ligand discovery and optimization. Curr Opin Chem Biol 2004; 8(4): 387-391.
25. Swayze EE, Jefferson EA, Sannes-Lowery KA, Blyn LB, Risen LM, Arakawa S, Osgood SA, Hofstadler SA, Griffey RH. SAR by MS:a ligand-based technique for drug lead discovery against RNA targets. J Med Chem 2002; 45(18): 3816-3819.
26. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-based lead discovery using X-ray crystallography. J Med Chem 2005; 48(2): 403-413.
27. Lofas S. Optimizing the hit-to-lead process using SPR analysis. Assay Drug Dev Technol 2004;4:407-415.
28. Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat Rev Drug Discov 2004;3:660-672.
29. Brenner S, Lerner RA. Encoded combinatorial chemistry. Proc Natl Acad Sci USA 1992;89:5381-5383.
30. Scheuermann J, Dumelin CE, Melkko S, Neri D. DNA-encoded chemical libraries. J Biotechnol 2006;126:568-581.
31. Landro JA, Taylor ICA, Stirtan WG, Osterman DG, Kristie J, Hunnicutt EJ, Rae PMM, Sweetnam PM. HTS in the new millennium. The role of pharmacology and flexibility. J Pharmacol Toxicol Methods 2000;44:273-289.
32. Kokko L, Johansson N, Lovgren T, Soukka T. Enzyme inihibitor screening using a homogenous proximity-based immunoassay for estradiol. J Biomol Screen 2005;10:348-354.
33. Kimberly H, Clement, JF, Abrahamyan L, Strebel K, Bouvier M, Kleinman L, Mouland AJ. A human immunodeficiency virus type 1 protease biosensor using bioluminescence resonance energy transfer. J Virol Methods 2005;128:93-103.
34. Thomsen W, Frazer J, Unett D. Functional assays for screening GPCR targets. Curr Opin Biotechnol 2005;16:655-665.
35. Westby M, Nakayama GR, Butler SL, Blair WS. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inihibitors. Antiviral Res 2005;67:121-140.
36. Mascini M, Bagni G, Di Pietro ML, Ravera M, Baracco S, Osella D. Electrochemical biosensor evaluation of the interaction between DNA and metallo-drugs. Biometals 2006;19:409-418.
37. Huber W. New strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. J Mol Recognition 2005;18:273-281.
38. Hanes J, Pluckhun A. In vitro selection and evolution of functional proteins by using ribosomal display. Proc Natl Acad Sci USA 1997;94:4937-4942.
39. Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, Viti F, Neri D. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005;5:2340-2350.
40. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997;15:553-557.
41. Patil SD, Rhodes DG, Burgess DJ. DNA- based therapeutics and DNA delivery systems:a comprehensive review. AAPS 2005;7(1):E61-E77.
42. Klumpp C, Kostarelos K, Prato M, Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta 2006;1758:404-412.
43. Proudfoot JR. Drugs, leads and drug-likeness:an analysis of some recently launched drugs. Bioorg Med Chem Lett 2002; 12(12): 1647-1650.
44. Makara GM, Athanasopoulos J. Ligand affinity binding in improving success-rates for lead generation. Curr Opin Biotechnol 2005;16:666-673.
45. Golebiowski A, Klopfenstein SR, Portlock DE. Lead compounds discovered from libraries:part 2. Curr Opin Chem Biol 2003;7:308-325.
46. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
47. Lipinski CA, Lambardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25.
48. Amidon GLH, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification:the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3): 413-420.
49. Schmeichel KL, Bissell MJ. Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 2003; 116(12): 2377-2388.
50. Leppert PS, Fix JA. Use of everted intestinal rings for in vitro examination of oral absorption potential. J Pharm Sci 1994;8:976-981.
51. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed:a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 1988;10:651-654.
52. Hidalgo IJ. Cultured intestinal epithelial cell models. Pharm Biotechnol 1996;8:35-50.
53. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. MDCK(Madin-Darby canine kidney) cells:a tool for membrane permeability screening. J Pharm Sci 1999;88:28-33.
54. Stewart BH, Chan OH, Lu RH, Rener EL, Schmid HL, Hamilton HW, Steinbaugh BA, Taylor MD. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models:relationship to absorption in humans. Pharm Res 1995;12:693-699.
55. White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 2000;40:133-157.
56. Pidgeon C, Ong S, Munroe J, Hornback WJ, Kasher JS, Grunz L, Liu H, Qiu X, Pidgeon M, Dantzig A. IAM chromatography:an in vitro screen for predicting drug membrane permeability. Med Chem 1995;38:590-594.
57. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening:parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998;41:1007-1010.
58. Bubik M, Ott M, Mahringer A, Fricker G. Rapid assessment of P-glycoprotein-drug interactions at the blood-brain barrier. Anal Biochem 2006;358:51-58.
59. Gray AC, Malton J, Clothier RH. The development of a standardised protocol to measure squamous differentiation in stratified epithelia, by using the fluorescein cadaverine incorporation technique Altern Lab Anim 2004; 32(2): 91-100.
60. Gray TE, Guzman K, Davis CW, Abdullah LH, Nettesheim P. Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol 1996; 14(1): 104-112.
61. Deli MAM, Abraham CS, Kataoka Y, Niwa M. P ermeability studies on in vitro blood-brain barrier models:physiology, pathology and pharmacology. Cell Mol Neurobiol 2005;25:59-126.
62. Combes RD, Balls M, Bansil L, Barratt M, Bell D, Botham P, Broadhead C, Clothier R, George E, Fentem J, Jackson M, Indans I, Loizou G, Navaratnam V, Pentreath V, Phillips B, Stemplewski H, Stewart J. The Third FRAME Toxicity Committee:Working Toward Greater Implementation of Alternatives in Toxicity Testing. Altern Lab Anim 2002;32(S1):635-642.
63. Gumbleton M, Audus KL. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 2001;90:1681-1698.
64. Atterwill CK, Purcell WM. Brain spheroid and other organotypic culture systems in in vitro neurotoxicology. In Pentreath VW, Ed., Neurotoxicology In vitro Washington DC:Taylor and Francis;1999, pp 213-238.
65. Harkema JR. Comparative structure, function and toxicity of the nasal airways. Predicting human effects from animal studies. In Gardner DE, Crapo JD, McCellan RO, Eds. Toxicology of the Lung. Washington DC:Taylor and Francis;1999, pp 55-83.
66. Dimova S, Brewster ME, Noppe M, Jorissen M, Augustijns P. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol In Vitro 2005;19:107-122.
67. Daly AK. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
68. Coecke S, Rogiers V, Bayliss M, Castell JM, Doehmer J, Fabre G, Fry J, Kern A, Westmoreland C. The use of long-term hepatocyte cultures for detecting induction of drug metabolising enzymes:the current status:ECVAM Hepatocytes and Metabolically Competent Systems Task Force Report 1. Altern Lab Anim 1999; 27(4): 579-638.
69. Kim HS, Wainer IW. On-line drug metabolism in capillary electrophoresis. 1. Glucuronidation using rat liver microsomes. Anal Chem 2006;78:7071-7077.
70. Dunn JC, Tompkins RG, Yarmush ML. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog 1991;7:237-245.
71. Scmitmeier S, Langsch A, Bader A. A membrane-based small-scale bioreactor for accelerated in vitro drug screenings with primary hepatocytes. Desalination 2006;199:258-260.
72. Fearn RA, Hirst BH. Predicting oral drug absorption and hepatobiliary clearance:human intestinal and hepatic in vitro cell models. Environ Toxicol Pharmacol 2006;21:168-178.
73. Krebsfaenger N, Murdter TE, Zanger UM, Eichelbaum MF, Doehmer J. V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans. ALTEX 2003; 20(3): 143-154.
74. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004;337:1-13.
75. Prabhakaran K, Sampson DA, Hoehner JC. Neuroblastoma survival and death:an in vitro model of hypoxia and metabolic stress. J Surg Res 2004;116:288-296.
76. Canova N, Kmonickova E, Lincova D, Vitek L, Farghali H. Evaluation of a flat membrane hepatocyte bioreactor for pharmacotoxicological applications:evidence that inhibition of spontaneously produced nitric oxide improves cell functionality. Altern Lab Anim 2004;32:25-35.
77. Wong JM, Harper PA, Meyer UA, Bock KW, Morike K, Lagueux J, Ayotte P, Tyndale RF, Sellers EM, Manchester DK, Okey AB. Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics 1991;1:66-67.
78. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003;33:23-30.
79. Refsgaard HHF, Jensen BF, Christensen IT, Hagen N, Brockhoff PB. In silico prediction of cytochrome P450 inihibitors. Drug Dev Res 2006;67:417-429.
80. Singh SB, Shen LQ, Walker MJ, Sheridan RP. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 2003;46:1330-1336.
81. Crivori P, Pogessi I. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur J Med Chem 2006;41:795-808.
82. Chovan LE, Black-Schaefer C, Dandliker PJ, Lau YY. Automatic mass spectrometry method development for drug discovery:application in metabolic stability assays. Rapid Commun Mass Spectrom 2004;18:3105-3112.
83. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005;21:11-16.
84. Bhogal N, Combes R. TGN1412:time to change the paradigm for the testing of new pharmaceuticals. Altern Lab Anim 2006; 34(2): 225-239.
85. Fort DJ, Paul RR. Enhancing the predictive validity of Frog Embryo Teratogenesis Assay-Xenopus(FETAX). J Appl Toxicol 2002;22:185-191.
86. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use(25 October 2006). ICH Considerations:General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors. Available from http://www.ich.org/LOB/media/MEDIA3363.pdf(accessed 29 January 2007).
87. Alonso MJ. Nanoparticles for overcoming biological barriers. Biomed Pharmacother 2004;58:168-172.
88. Sadrieh N. Nanaotechnology:regulatory perspective for drug development http://www.fda.gov/nanotechnology/powerpoint_conversions/regulatory_perspective_files/outline/index.html(accessed 29 January 2007).
89. Oberdörster G, Maynard A, Donaldson K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, Warheit S, Yang H. Principles of characterizing the potential health effects from exposure to nanomaterials:elements of a screening strategy. A report from ILSI Research Foundation/Risk Science Instate Nanomaterial Toxicity Screening Working Groups. Particle Fibre Toxicol 2005;2:1-36.
90. Labhesetwar V, Song C, Humphrey W, Shebucki R, Levy RJ. Arterial uptake of biodegradable nanoparticles:effects of surface modifications. J Pharm Sci 2000;87:1229-1234.
91. Environmental Toxicity Council(ETC) Group:Size matters! The case for a global moratorium. 2003 /04. Occasional paper series vol 7 no 1. Available from http://etcgroup.org/en/materials/publications.html?id=165(accessed 10 September 2007).
92. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines:from toxicology to pharmacology. Adv Drug Dev Rev 2006;58:1460-1470.
93. Nel A, Xia T, Maedler L, Li N. Toxic potential of materials at the nanolevel. Science 2006;311:622-627.
94. Lawrence CL, Pollard CE, Hammond TG, Valentin JP. Nonclinical proarrhythmia models:predicting torsades des pointes. J Pharmacol Toxicol Methods 2005;52:46-59.
95. De Pont FI, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades des pointes with non-antiarrhythmic drugs:a call for consensus. Eur J Clin Pharmacol 2001;57:185-209.
96. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K + channel blockade:current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005;25:133-166.
97. Lavon N, Bevenisty N. Differentiation and genetic manipulation of human embryonic stem cells and the analysis of the cardiovascular system. Trends Cardiovasc Med 2003;13:47-52.
98. He JQ, Ma Y, Lee Y, Thompson JA, Kamp T. Human embryonic stem cells develop into multiple types of cardiac myocytes:action potential characterisation. Circ Res 2003;93:1-9.
99. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Bioeng Biomembr 1999;28:379-385.
100. Draft ICCVAM test method recommendations:In Vitro Pyrogenicity Test Methods(December 2006). Available from http://iccvam.niehs.nih.gov/methods/pyrodocs/supp/PWGrec12016.pdf(accessed 29 January 2007).
101. Willingham AT, Orth OP, Batalov S, Eters EC, Wen BG, Aza-Blanc P, Hogenesch JB, Sculz PG. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science 2005;309:1570-1573.
102. Yoon BI, Li GX, Kitada K, Kawasaki Y, Igarashi K, Kodama Y, Inoue T, Kobayashi K, Kanno J, Kim DY, Inoue T, Hirabayashi Y. Mechanisms of benzene-induced hematotoxicity and leukemogenicity:cDNA microarray analyses using mouse bone marrow tissue. Environ Health Perspect 2003;111:1411-1420.
103. Kramer JA, Curtiss SW, Kolaja KL, Alden CL, Blomme EA, Curtiss WC, Davila JC, Jackson CJ, Bunch RT. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem Res Toxciol 2004;17:463-470.
104. Nilsson P, Paavilainen L, Larsson K, Odling J, Sundberg M, Andersson AC, Kampf C, Persson A, Al-Khalili Szigyarto C, Ottosson J, Bjorling E, Hober S, Wernerus H, Wester K, Ponten F, Uhlen M. Towards a human proteome atlas:high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics 2005;5:4327-4337.
105. Nicholson JK, Lindon JC, Holmes E. " Metabonomics ":understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-1189.
106. Bollard ME, Murray AJ, Clarke K, Nicholson JK, Griffin JL. A study of metabolic compartmentation in the rat heart and cardiac mitochondritiss using high resolution magic angle spinning 1 H NMR spectroscopy. FEBS Lett 2003;553:73-78.
107. Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 2005;18:143-162.
108. Viravaidya K, Sin A, Shuler ML. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog 2004;20:316-323.
109. Ziauddin J, Sabatini DM. Microarrays of cells expressing defined cDNAs. Nature 2001;411:107-110.
110. Hung PJ, Lee PJ, Sabouchi P, Lin R, Lee P. Continuous perfusion microfluidic cell culture array for high-throughput cell-based assays. Biotechnol Bioeng 2005;89:1-8.
111. Keun HC. Metabonomic modelling of drug toxicity. J Pharmacol Exp Ther 2006;109:92-106.
112. Butcher EC, Berg EL, Kunkel EJ. System biology in drug discovery. Nat Biotechnol 2004;22:1253-1259.
113. Ekins S, Nikolsky Y, Nikolskaya T. Techniques:application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharm Sci 2005;26:202-209.
114. Wilson AG, White AC, Mueller RA. Role of predictive metabolism and toxicity modelling in drug discovery-a summary of some recent advancements. Curr Opin Drug Discov Dev 2003;9:74-83.
115. Rester U. Dock around the clock-current status of small molecule docking and scoring. QSAR Comb Sci 2006;25:605-615.
116. Barratt M, Langowski J. Validation and development of the DEREK skin sensitisation rulebase by anaylsis of the BgVV list of contact allergens. In Balls M, Zeller AM, Halder M, Eds. Progress in the Reduction Refinement and Replacement of Animal Experimentation. New York:Elsevier;2000, pp 493-512.
117. Zinke S, Gerner I, Schlede E. Evaluation of a rule base for identifying contact allergens by using a regulatory database:comparison of data on chemicals notified in the European Union with " structural alerts " used in the DEREK expert system. Altern Lab Anim 2002;30:285-298.
118. Dearden JC, Barratt MD, Benigni R, Bristol DW, Combes RD, Cronin MTD, Judson PN, Payne MP, Richard AM, Tichy N, Worth AP, Yourick JJ. The development and validation of expert systems for predicting toxicity. Altern Lab Anim 1997;25:223-252.
119. Matthews EJ, Contrera JF. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul Toxicol Pharmacol 1998;28:242.
120. Enslein K, Gombar VK, Blake BW. International Commission for Protection Against Environmental Mutagens and Carcinogens. Use of SAR in computer-assisted prediction of carcinogenicity and mutagenicity of chemicals by the TOPKAT program. Mutat Res 1994;305:47.
121. Woo YT, Lai D, Argus A, Arcos JC. Development of structure-activity relationship rules for predicting carcinogenic potential of chemicals. Toxicol Lett 1995;79:219.
122. Lewis DFV, Bird MG, Jacobs MN. Human carcinogens:an evaluation study via the COMPACT and HazardExpert procedures. Hum Exp Toxicol 2002;21:115.
123. Ji ZL, Wang Y, Yu L, Ha LH, Zheng CJ, Chen YZ. In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. Toxicol Lett 2006;164:104-112.
124. Blaauboer BJ. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamics modelling as a tool in hazard and risk assessment:a commentary. Toxicol Lett 2003;138:161-171.
125. Deglmann CJ, Ebner T, Ludwig E, Happich S, Schildberg FW, Koebe HG. Protein binding capacity in vitro changes metabolism of substrates and influences the predictability of metabolic pathways in vivo. Toxicol In Vitro 2004;18:835-840.
126. Chang C, Ray A, Swaan P. In silico strategies for modelling membrane transporter function. Drug Discov Today 2005;10:663-671.
127. Poole TB, Ed. The UFAW Handbook on the Care and Management of Laboratory Animals. London:UFAW;1999.
128. Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, Medhurst AD. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modelling. Mol Pharmacol 2003; 64(6): 1295-1308.
129. Morton DM. Importance of species selection in drug toxicity testing. Toxicol Lett 1998;102-103:545-550.
130. Tang-Wai DF, Kajiji S, diCapua F, de Graff D, Roninson IB, Gros P. Human(MDR1) and mouse(mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995;34:32-39.
131. Tang H, Mayersohn M. Accuracy of allometrically predicted pharmacokinetic parameters in humans:role of species selection. Drug Metab Dispos 2005;33:1288-1295.
132. Festing M, Ed. The Design of Animal Experiments:Reducing the Use of Animals in Research Through Better Experimental Design. London:Royal Society of Medicine Press Ltd, 2002.
133. Morris T, Goulet S, Morton D. The International Symposium on Regulatory Testing and Animal Welfare:recommendations on best scientific practices for animal care in regulatory toxicology. ILAR J 2002;43(Suppl):S123-S125.
134. Gold LS, Bernstein L, Magaw R, Slone TH. Inter-species extrapolation in carcinogenesis:prediction between rats and mice. Environ Health Perspect 1989;81:211-219.
135. Krauthammer M, Kaufmann CA, Gilliam TC, Rzhietsky A. Molecular triangulation:bridging linkage and molecular-network information for identifying candidate genes in Azheimer's disease. Proc Natl Acad Sci USA 2004;101:15148-15153.
136. TM. Elsevier MDL. Available from http://www.mdl.com/products/knowledge/pharmapendium/index.jsp(accessed 29 January 2007).
137. TM. Wolters-Kluwer Health. Medi-Span Available from http://www.medispan.com/Products/index.aspx?id=18(accessed 29 January 2007).
138. Sobels FH. Evaluating the mutagenic potential of chemicals:the minimal battery and extrapolation problems. Arch Toxicol 1980;46:21-30.
139. Sutter TR. Molecular and cellular approaches to extrapolation for risk assessment. Environ Health Perspect 1995;103:386.
140. Van Ravenzwaay B, Leibold E. The significance of in vitro rat skin absorption studies to human risk assessment. Toxicol In Vitro 2004;18:219-225.
141. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans:how animals help. Nat Rev Drug Discov 2004;3:226-236.